Minitouch is a third-generation endometrial ablation system that has been used successfully for over a decade in Europe. Now FDA-approved in the United States, it offers a safe, effective, and minimally invasive treatment option for women suffering from heavy menstrual bleeding.
Minitouch has been a trusted solution for endometrial ablation in Europe for more than a decade. Thousands of patients have benefited from its gentle, low-temperature energy delivery, proving its long-term safety and effectiveness.
Minitouch is widely adopted by physicians who appreciate its simplicity, efficiency, and excellent patient outcomes. With thousands of successful procedures performed, it has established itself as a preferred in-office treatment for heavy menstrual bleeding.

Significant reduction in heavy bleeding for the majority of patients

Minimal discomfort during and after the procedure

Rapid recovery times, with most patients resuming normal activities within 24 hours
Minitouch was rigorously tested in an FDA clinical trial to ensure safety, efficacy, and superior patient outcomes. The trial demonstrated:
Long-term data from clinical studies confirm that Minitouch delivers lasting relief from heavy bleeding and painful periods. Patients report:
Sustained improvements
in menstrual flow reduction
High satisfaction rates
with 94% reporting normal, light, or no periods after treatment
Consistent symptom relief
even three years post-procedure
Unlike some second-generation ablation technologies, Minitouch is designed to safely treat a broader range of patients, including those with:
This means more women can benefit from a safe, effective, and in-office alternative to hysterectomy.
for heavy menstrual bleeding. Physicians trust it, patients benefit from it, and the results speak for themselves.
Minitouch’s 3rd-Generation Technology empowers OB/GYNs to deliver effective, gentle care—no anesthesia, no cervical dilation, just life-changing outcomes in minutes.
© 2025 uinoted.com | All Rights Reserved.